Competition in first line kidney cancer is heating up after Germany’s Merck KGaA and Pfizer briefed the ESMO conference with detailed results of their combination of the Bavencio immunother
Germany’s Merck KGaA has said it is “encouraged” by mid-stage trial results showing that its Bruton’s kinase (BTK) class drug evobrutinib reduced occurrence of central nervous system lesion
A combination therapy based around Pfizer and Merck KGaA’s Bavencio has outperformed standard of care in a late-stage trial in untreated but advanced kidney cancer.
Data and analytics firm GlobalData has tracked the market cap and performance of the top 25 pharma companies for the first quarter of this year – and there are some notable changes compared
